tag genetic-testing 
Delveinsight
FEBRUARY 25, 2021
Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing.
The Pharma Data
MARCH 23, 2022
Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. Early in infection, it appears that host cellular proteins are in defense mode against Ebola virus polymerase and the viral genetic material.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 10, 2023
Bethyl antibodies are highly regarded for passing strict validation testing before arriving in customer hands. Pillar 5: Protein OE/Epitope Tags. Pillar 6: Genetic Strategies. The principles that have guided our rigorous validation practices for decades preceded a publication (Uhlen et al.,
Drug Discovery World
JANUARY 30, 2024
Lentivirus strategies are one of the most widely used tools in biomedical research and clinical testing, says Stella Vnook, CEO, Likarda. “Dr Dr Naldini open new doors for cures for otherwise untreatable genetic diseases with the full impact of his work still untapped”, she said.
The Pharma Data
OCTOBER 21, 2020
The disease is a subtype of ALL in which the cancer cells have a genetic abnormality called the Philadelphia chromosome (Ph). Traditionally, Ph-positive ALL had a poor prognosis, but in the past two decades that has changed with the introduction of drugs that target the genetic anomaly. The patients were followed for up to two years.
The Pharma Data
OCTOBER 21, 2020
The disease is a subtype of ALL in which the cancer cells have a genetic abnormality called the Philadelphia chromosome (Ph). Traditionally, Ph-positive ALL had a poor prognosis, but in the past two decades that has changed with the introduction of drugs that target the genetic anomaly. The patients were followed for up to two years.
pharmaphorum
DECEMBER 23, 2022
price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. CellCentric, a U.K-based
Expert insights. Personalized for you.
52 
Let's personalize your content